Study Title
Screening For HIV-Associated Anal Cancer
This study is also referred to as the TRACE 2 study (Toronto Research in Anal Cancer Evaluation).

Status
Study is complete.
TRACE2 program is continuing.

Primary Investigators at TGH
Dr. Irving Salit
Dr. Jill Tinmouth

Sponsor
Ontario HIV Treatment Network (OHTN)
Canadian Foundation for AIDS Research (CANFAR)

Brief Description of the Study
Enrolment of 400 HIV positive MSM (male who have sex with men) participants has been achieved and our participants have completed the study. We are starting phase 2 of TRACE, called TRACE2. For TRACE2, we will continue to monitor our study participants and obtain swabs from various body sites for HPV detection. In addition, we are enrolling the partners of our original study participants, and inviting them to get some early anal cancer screening done in the form of an anal Pap smear.

Due to the high demand for high resolution anoscopy (HRA) and limited clinical time available, Dr Salit and Dr Tinmouth are no longer accepting new patients for high resolution anoscopy (HRA) outside the context of the study.

Study
• Baseline anal cancer screening to see which are the best tests for screening

Post-study Program
• Continued screening for anal cancer and pre-cancer
• Treatment of those with dysplasia (pre-cancer)
• Continued monitoring of participants with high grade dysplasia (AIN 3)

Contact
For more information contact Marie Sano @ 416-340-4800 ext: 8172,
Email: marie.sano@uhn.on.ca